How does this UK gene therapy compare to international trials?

Question

Accepted Answer

UK Gene Therapy Compared to International Efforts

The UK's gene therapy trial for hereditary deafness, which has shown promising results in young children, is part of a global effort involving similar treatments being developed and tested in other countries, including China and the United States. While the UK trial, led by ear surgeon Manohar Bance at Addenbrooke’s Hospital in Cambridge, utilizes a therapy developed by US biotech firm Regeneron, other nations are pursuing comparable approaches with variations in technology and delivery methods. These international efforts collectively aim to address genetic mutations responsible for deafness, offering hope for significant hearing restoration.
International Collaboration and Competition in Gene Therapy

The gene therapy trial in Cambridge is not an isolated initiative. China is actively working on targeting the same OTOF gene, which is implicated in hereditary deafness, although their approach involves a different technology and mode of delivery compared to the UK's treatment. Similarly, medical professionals in Philadelphia have reported positive outcomes using a form of gene therapy on an 11-year-old boy, indicating parallel advancements in the United States. These parallel developments highlight a global race and collaborative spirit in developing effective treatments for genetic hearing loss.
Variations in Treatment Modalities and Scope

The specific gene therapy administered in the UK trial, developed by Regeneron, focuses on delivering a functional copy of the OTOF gene to the inner ear. This OTOF gene is crucial for producing otoferlin, a protein essential for communication between inner ear cells and the auditory nerve. While the precise details of the technologies and delivery mechanisms used in Chinese and US trials are not fully elaborated, the core objective remains the same: to correct the genetic defect causing deafness. The Cambridge trial itself is structured in phases, beginning with low and high doses in one ear before potentially progressing to simultaneous bilateral administration, involving up to 18 participants from the UK, Spain, and the US over a five-year follow-up period.
Early Successes and Future Prospects

The initial results from the Cambridge trial have been described as "spectacular," with 18-month-old Opal, the first participant, showing hearing close to normal after surgery in September, with further improvements anticipated. A second child in the same trial also demonstrated positive results six weeks post-surgery. These outcomes, alongside reports from Philadelphia, suggest that gene therapy is moving beyond theoretical potential into tangible clinical success. While implants have been the standard treatment for auditory neuropathy, these gene therapy trials represent a potential paradigm shift, offering the prospect of a functional cure for certain forms of deafness.

Reading history

Hide →

This history is cleared when the page is closed.

How does this UK gene therapy compare to international trials?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends